BMRN
$54.13-0.90 (-1.64%)
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...
Recent News
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
How The BioMarin (BMRN) Story Is Shifting With Voxzogo Risks And The Amicus Deal
Price targets on BioMarin Pharmaceutical now span the mid US$50s to just above US$100, reflecting a wide reset in expectations across Wall Street. Analysts anchor their views in different readings of Voxzogo’s long term potential, the planned Amicus acquisition, and how much credit to give the broader rare disease portfolio and pipeline. As you read on, you will see what is driving these shifts and how to keep track of an analyst narrative that is still very much in motion. Stay updated as...
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s approved treatment for achondroplasia. ​Achondroplasia is a genetic condition that causes dwarfism and stunted growth in children. The recent […]